Journal of Andrology Proceedings of the Fifth International Conference on the Epididymis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Right arrow Return to article

Characteristics of included studies
    Number of Patients (Intervention/Control)   Intervention   Treatment Duration   Outcome Parameters   Methodological Quality
  Mehik 2003   17/20   Alfuzosin 5 mg twice daily   6 mo   NIH-CPSI   C:B J:4
  Alexander 2004   87/87   Tamsulosin 0.4 mg/d   6 wk   NIH-CPSI   C:A J:5
  Gul 2001   39/30   Terazosin 2 mg/d   3 mo   I-PSS   C:B J:2
  Evliyaoglu 2002   30/30   Doxazosin 1 mg~4 mg   3 mo   I-PSS   C:B J:2
  Cheah 2003   43/43   Terazosin 1 mg~5 ng   3.5 mo   NIH-CPSI I-PSS   C:B J:3
  Nickel 2004   27/30   Tamsulosin 0.4 mg   6 wk   NIH-CPSI   C:B J:3
  Shen 2004   40/40   Terazosin 2 mg/d   6 wk   NIH-CPSI   C:B J:1
  Lu 2004   20/17   Phenoxybenzamine Hydrochloride 10 mg twice daily   4 wk   NIH-CPSI   C:B J:4
  Wang 2002   74/60   Terazosin 2 mg twice daily   3 mo   NIH-CPSI   C:B J:1





Right arrow Return to article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS